Shots: Sanofi has signed an exclusive worldwide licensing agreement with C4XD worth up to $492.94M million, for C4XD’s oral pre-clinical IL-17A inhibitor program C4XD to receive $8.33M up front and is eligible to receive up to $484.60M as development, regulatory and commercial milestones including $13.09M as pre-clinical milestones along with royalties Sanofi will develop and […]Read More
Shots: In the P-I SPICE study, the companies will evaluate the clinical combination of BMS’ Opdivo with PsiOxus’ NG-641 and optimize the combination IV dosing regimen in late-stage cancer patients to treat a range of tumor types PsiOxus will be responsible to conduct P-I study with patient recruitment expected to initiate in Q3’21 NG-641 is […]Read More
Shots: Menicon to develop and manufacture contact lenses to help manage the progression of myopia in children. J&J Vision will focus on expanding the availability of these lenses across the globe The collaboration will combine the expertise of both the companies and allow J&J to bring a portfolio of differentiated products that helps in managing […]Read More
Shots: The companies collaborated to accelerate digital health solutions with the goal of improving the patient’s outcomes and care with chronic illness MGH will utilize AstraZeneca’s AMAZE disease management platform for heart failure and asthma management studies. The companies plan to expand the use of AMAZE across multiple chronic diseases, following the success of heart […]Read More
Shots: The companies collaborated to develop the personalized medicines for patients with ultra-rare diseases. The collaboration involves additional resources, financial contribution, and experience from both the company The alliance strengthens n-Lorem’s mission to bring immediate hope and rapid treatment to ultra-rare disease patients in need n-Lorem Foundation provides a free and lifetime supply of ASO […]Read More
Shots: AbCellera to receive upfront, milestone, and royalties based on the development and commercialization of Abs, emerge under the collaboration The expanded collaboration will utilize AbCellera’s technology stack, which includes Trianni Mouse and OrthoMab protein engineering platform AbCellera will generate panels of Abs against up to 8 new targets across multiple indications, selected by Gilead […]Read More
Shots: Fresenius to provide NxStage HHD machines, dialysis supplies, and a connected health platform to DaVita patients to empower more people living with kidney failure to select home dialysis in the US The agreement allows patients to access the Nx2me connected health platform that collects and share treatment information with care team. The connected health […]Read More
Shots: mAbxience will equip their state-of-the-art cGMP facility in Spain with an ABEC 4,000L CSR Bioreactor The system will be commissioned mid-2021 and will increase biosimilar and CDMO manufacturing capacity at the León site The 4,000L volume & performance comparable to stainless steel systems will enable mAbxience to improve flexibility, productivity and efficiency. The CSR […]Read More
Shots: Evotec to receive research funding and will be eligible for $160M/program as discovery, pre/ clinical, a commercial milestone along with royalties on sales of product emerges from the collaboration The collaboration will utilize Evotec’s RNA targeting platform to identify RNA sequences to target with small-molecule ligands aligned that can be developed into the first-in-class […]Read More
Shots: Anima to receive ~ $120M up front, preclinical milestones and ~$1.1B as clinical and commercial milestones along with royalties on each product emerge under the collaboration Takeda gets an exclusive right to develop and commercialize the mRNA transational modulators and has a time limited option to expands the collaboration for three additional targets for […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
